177lu-psma-617
novartis
['pcsm', 'crpc']
vision post-hoc study suv mean prognostic of rpfs, os, orr, psa outcomes w/lupsma-617 (suv mean of 10 appears to be psma high cutoff for sig increased rpfs, os), absence of liver/bone but +ln mets do best w/lupsma #mcrpc #asco22 #pcsm 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope